D
Deborah Morosini
Researcher at Foundation Medicine
Publications - 28
Citations - 2599
Deborah Morosini is an academic researcher from Foundation Medicine. The author has contributed to research in topics: Targeted therapy & Cancer. The author has an hindex of 17, co-authored 28 publications receiving 2080 citations.
Papers
More filters
Journal ArticleDOI
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors
Garrett M. Frampton,Siraj M. Ali,Margaret Rosenzweig,Juliann Chmielecki,Xinyuan Lu,Todd M. Bauer,Mikhail Akimov,Jose A. Bufill,Carrie B. Lee,David Jentz,Rick Hoover,Sai-Hong Ignatius Ou,Ravi Salgia,Tim Brennan,Zachary R. Chalmers,Savina Jaeger,Alan Huang,Julia A. Elvin,Rachel L. Erlich,Alex Fichtenholtz,Kyle Gowen,Joel R. Greenbowe,Adrienne Johnson,Depinder Khaira,Caitlin McMahon,Eric M. Sanford,Steven Roels,Jared White,Joel Greshock,Robert Schlegel,Doron Lipson,Roman Yelensky,Deborah Morosini,Jeffrey S. Ross,Eric A. Collisson,Malte Peters,Philip J. Stephens,Vincent A. Miller +37 more
TL;DR: Analysis of tumor genomic profiles from 38,028 patients is reported to identify 221 cases with METex14 mutations, including 126 distinct sequence variants, and identify a unique subset of patients likely to derive benefit from MET inhibitors.
Journal ArticleDOI
New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
Jeffrey S. Ross,Jeffrey S. Ross,Kai Wang,Rami N. Al-Rohil,Janne V. Rand,David M. Jones,Hwa J. Lee,Christine E. Sheehan,Geoff Otto,Gary A. Palmer,Roman Yelensky,Doron Lipson,Deborah Morosini,Matthew J. Hawryluk,Daniel V.T. Catenacci,Vincent A. Miller,Chaitanya Churi,Siraj M. Ali,Philip J. Stephens +18 more
TL;DR: Two thirds of patients in this study harbored genomic alterations that are associated with targeted therapies and that have the potential to personalize therapy selection for to individual patients.
Journal ArticleDOI
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
Robert C. Doebele,Lara E. Davis,Aria Vaishnavi,Anh T. Le,Adriana Estrada-Bernal,Stephen B. Keysar,Antonio Jimeno,Marileila Varella-Garcia,Dara L. Aisner,Yali Li,Philip J. Stephens,Deborah Morosini,Brian B. Tuch,Michele Fernandes,Nisha Nanda,Jennifer A. Low +15 more
TL;DR: A patient with a metastatic soft-tissue sarcoma with an LMNA-NTRK1 fusion had rapid and substantial tumor regression with a novel, highly selective TRK inhibitor, LOXO-101, providing the first clinical evidence of benefit from inhibiting TRK fusions.
Journal ArticleDOI
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
Jie He,Omar Abdel-Wahab,Michelle Nahas,Kai Wang,Raajit K. Rampal,Andrew M. Intlekofer,Jay Patel,Andrei V. Krivstov,Garrett M. Frampton,Lauren Young,Shan Zhong,Mark Bailey,Jared White,Steven Roels,Jason Deffenbaugh,Alex Fichtenholtz,Tim Brennan,Margaret Rosenzweig,Kimberly Pelak,Kristina M. Knapp,Kristina W. Brennan,Amy Donahue,Geneva Young,Lazaro Garcia,Selmira T. Beckstrom,Mandy Zhao,Emily White,Vera Banning,Jamie Buell,Kiel Iwanik,Jeffrey S. Ross,Deborah Morosini,Anas Younes,Alan M. Hanash,Elisabeth Paietta,Kathryn G. Roberts,Charles G. Mullighan,Ahmet Dogan,Scott A. Armstrong,Tariq I. Mughal,Tariq I. Mughal,Jo Anne Vergilio,Elaine LaBrecque,Rachel L. Erlich,Christine Vietz,Roman Yelensky,Philip J. Stephens,Vincent A. Miller,Marcel R.M. van den Brink,Geoff Otto,Doron Lipson,Ross L. Levine +51 more
TL;DR: A novel next-generation sequencing-based assay to identify all classes of genomic alterations using archived formalin-fixed paraffin-embedded blood and bone marrow samples with high accuracy in a clinically relevant time frame is developed, which increases the ability to identify clinically relevant genomic alterations with therapeutic relevance.
Journal ArticleDOI
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
Jeffrey S. Ross,Jeffrey S. Ross,Kai Wang,Geoff Otto,Emily White,Kiel Iwanik,Gary A. Palmer,Roman Yelensky,Doron Lipson,Juliann Chmielecki,Rachel L. Erlich,Andrew Rankin,Siraj M. Ali,Julia A. Elvin,Deborah Morosini,Vincent A. Miller,Philip J. Stephens +16 more
TL;DR: Almost all CUP samples harbored at least 1 clinically relevant GA with potential to influence and personalize therapy and the ACUP tumors were more frequently driven by GAs in the highly druggable RTK/Ras/mitogen-activated protein kinase (MAPK) signaling pathway than the non-ACUP tumors.